PCI Pharma Services (PCI) has begun an expansion of its Tredegar facility in Wales, UK to enhance its high potent drug manufacturing and development capabilities, including both clinical and commercial supply.   The investment involves an extension to the contained oral solid dosage form manufacturing facility that will double the large-scale granulation and fluid bed drying capacity. It will also create additional space for new potent handling capabilities, additional analytical, and a small-...